Oral presentation
Advances in the therapy of lung cancer
08:30
LATE-BREAKING ABSTRACT: Overall survival after the introduction of CT-based follow-up after resection of lung cancer. A population based quality assurance analysis
N. Hansen(Odense C, Denmark)
COI
1
08:45
Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung: LUX-Lung 8 (LL8), a phase III trial
K. Syrigos(Athens, Greece)
COI
2
09:00
Enhanced FGFR signaling correlates with erlotinib/bevacizumab response in advanced non-squamous non-small cell lung cancer
A. Franzini(St. Gallen, Switzerland)
COI
3
09:15
Clinical characteristics of 32 patients with BRAF V600E-mutated lung adenocarcinoma
A. Benguigui(Rouen, France)
COI
4
09:30
Cox-2 inhibitors in the treatment of small cell lung cancer patients
E. Boutsikou(Thessaloniki, Greece)
COI
5
09:45
Does smoking status after a diagnosis of lung cancer matter? Impact of quitting on 1 year survival
R. Gemine(llanelli (Dyfed), United Kingdom)
COI
6
10:00
A phase III trial comparing concomitant radiochemotherapy (RT-CT) with cisplatin (P) and docetaxel (D) as induction versus consolidation in patients with locally advanced unresectable non-small cell lung cancer (NSCLC). An ELCWP study
T. Berghmans(Bruxelles, Belgium)
COI
7
10:15
Consolidation maintenance oral vinorelbine following concurrent chemoradiation of intravenous vinorelbine and cisplatin in patients with unresectable stage III non-small cell lung cancer
T. Salah(Assiut, Egypt)
COI
8
. . .
